Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Common Equity (2019 - 2025)

Biodesix (BDSX) has disclosed Common Equity for 7 consecutive years, with -$2.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity fell 111.81% year-over-year to -$2.5 million, compared with a TTM value of -$2.5 million through Dec 2025, down 111.81%, and an annual FY2025 reading of -$2.5 million, down 111.81% over the prior year.
  • Common Equity was -$2.5 million for Q4 2025 at Biodesix, down from -$1.7 million in the prior quarter.
  • Across five years, Common Equity topped out at $36.4 million in Q1 2021 and bottomed at -$7.0 million in Q2 2023.
  • Average Common Equity over 5 years is $11.0 million, with a median of $7.7 million recorded in 2022.
  • Peak annual rise in Common Equity hit 2026.49% in 2024, while the deepest fall reached 220.92% in 2024.
  • Year by year, Common Equity stood at $19.7 million in 2021, then rose by 4.46% to $20.6 million in 2022, then tumbled by 77.77% to $4.6 million in 2023, then surged by 355.81% to $20.9 million in 2024, then crashed by 111.81% to -$2.5 million in 2025.
  • Business Quant data shows Common Equity for BDSX at -$2.5 million in Q4 2025, -$1.7 million in Q3 2025, and $1.1 million in Q2 2025.